{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:20:36Z","timestamp":1772205636069,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"DOI":"10.7759\/cureus.104389","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:46:37Z","timestamp":1772203597000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Outcomes and Vascular Surrogate Markers in Rheumatoid Arthritis Patients Treated With Anti-Tumour Necrosis Factor (TNF) Therapy: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Danish","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashar","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warda Batool","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajia","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bismilla athar","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Taqi","family":"Askari Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eemahn","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tooba","family":"Babar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Anwar","family":"Mohamed Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaf","family":"Mohamed Osman Ali Mohamed Salih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam Ali","family":"Abu Odeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang S","year":"2022","unstructured":"Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci. 2022, 23:10.3390\/ijms23020905","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/life13020319","article-title":"Cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy","volume":"13","author":"Popescu D","year":"2023","unstructured":"Popescu D, Rezus E, Badescu MC, et al.. Cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life (Basel). 2023, 13:10.3390\/life13020319","journal-title":"Life (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186461","article-title":"Cardiovascular risk assessment in patients with rheumatoid arthritis","volume":"14","author":"Oiegar R","year":"2025","unstructured":"Oiegar R, Pop D. Cardiovascular risk assessment in patients with rheumatoid arthritis. J Clin Med. 2025, 14:10.3390\/jcm14186461","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501452R","article-title":"TNF-\u03b1 promotes synovial inflammation and cartilage bone destruction in rheumatoid arthritis via NF-\u03baB\/YY1\/miR-103a-3p axis","volume":"39","author":"Yuan Y","year":"2025","unstructured":"Yuan Y, Mu N, Li Y, et al.. TNF-\u03b1 promotes synovial inflammation and cartilage bone destruction in rheumatoid arthritis via NF-\u03baB\/YY1\/miR-103a-3p axis. FASEB J. 2025, 39:e70876. 10.1096\/fj.202501452R","journal-title":"FASEB J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma X","year":"2013","unstructured":"Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013, 1:177-84. 10.3892\/br.2012.42","journal-title":"Biomed Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000080","article-title":"Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis","volume":"1","author":"Nurmohamed M","year":"2015","unstructured":"Nurmohamed M, Bao Y, Signorovitch J, et al.. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015, 1:e000080. 10.1136\/rmdopen-2015-000080","journal-title":"RMD Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103488","article-title":"Safety of TNF-\u03b1 inhibitors therapy in patients with rheumatoid arthritis: an umbrella review","volume":"88","author":"Xiao R","year":"2025","unstructured":"Xiao R, Tang P, Zhou J, et al.. Safety of TNF-\u03b1 inhibitors therapy in patients with rheumatoid arthritis: an umbrella review. EClinicalMedicine. 2025, 88:103488. 10.1016\/j.eclinm.2025.103488","journal-title":"EClinicalMedicine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-025-00753-x","article-title":"The cardiovascular safety of tumour necrosis factor inhibitors in arthritic conditions: a structured review with recommendations","volume":"12","author":"Avouac J","year":"2025","unstructured":"Avouac J, Ait-Oufella H, Habauzit C, et al.. The cardiovascular safety of tumour necrosis factor inhibitors in arthritic conditions: a structured review with recommendations. Rheumatol Ther. 2025, 12:211-36. 10.1007\/s40744-025-00753-x","journal-title":"Rheumatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06505-y","article-title":"Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis","volume":"42","author":"Abdulmajid B","year":"2023","unstructured":"Abdulmajid B, Blanken AB, van Geel EH, et al.. Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023, 42:999-1011. 10.1007\/s10067-023-06505-y","journal-title":"Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S282691","article-title":"Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction","volume":"14","author":"Fragoulis GE","year":"2021","unstructured":"Fragoulis GE, Soulaidopoulos S, Sfikakis PP, et al.. Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction. J Inflamm Res. 2021, 14:1915-31. 10.2147\/JIR.S282691","journal-title":"J Inflamm Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82269","article-title":"Cardiovascular outcomes of disease-modifying antirheumatic drugs in rheumatoid arthritis: a review of the current evidence","volume":"17","author":"Sunkara P","year":"2025","unstructured":"Sunkara P, Garikipati NA, Nimmagadda R, et al.. Cardiovascular outcomes of disease-modifying antirheumatic drugs in rheumatoid arthritis: a review of the current evidence. Cureus. 2025, 17:e82269. 10.7759\/cureus.82269","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120541","article-title":"Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial","volume":"39","author":"Tam LS","year":"2012","unstructured":"Tam LS, Shang Q, Li EK, et al.. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial. J Rheumatol. 2012, 39:2267-75. 10.3899\/jrheum.120541","journal-title":"J Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon DH","year":"2023","unstructured":"Solomon DH, Giles JT, Liao KP, et al.. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Ann Rheum Dis. 2023, 82:324-30. 10.1136\/ard-2022-223302","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308953","article-title":"Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis","volume":"103","author":"O'Neill F","year":"2017","unstructured":"O'Neill F, Charakida M, Topham E, et al.. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart. 2017, 103:766-73. 10.1136\/heartjnl-2015-308953","journal-title":"Heart"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03352-3","article-title":"Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial","volume":"26","author":"Liao KP","year":"2024","unstructured":"Liao KP, Rist P, Giles J, et al.. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial. Arthritis Res Ther. 2024, 26:123. 10.1186\/s13075-024-03352-3","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.112038","article-title":"Most methodological characteristics do not exaggerate effect estimates in nutrition RCTs: findings from a meta-epidemiological study","volume":"189","author":"Bantle G","year":"2026","unstructured":"Bantle G, Stadelmaier J, Petropoulou M, et al.. Most methodological characteristics do not exaggerate effect estimates in nutrition RCTs: findings from a meta-epidemiological study. J Clin Epidemiol. 2026, 189:112038. 10.1016\/j.jclinepi.2025.112038","journal-title":"J Clin Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2445","article-title":"Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study","volume":"350","author":"Abraha I","year":"2015","unstructured":"Abraha I, Cherubini A, Cozzolino F, et al.. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. BMJ. 2015, 350:h2445. 10.1136\/bmj.h2445","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354593","article-title":"Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis","volume":"15","author":"Su L","year":"2024","unstructured":"Su L, Xu C, Huang H, et al.. Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis. Front Immunol. 2024, 15:1354593. 10.3389\/fimmu.2024.1354593","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Da\u00efen CI","year":"2012","unstructured":"Da\u00efen CI, Duny Y, Barnetche T, et al.. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012, 71:862-8. 10.1136\/annrheumdis-2011-201148","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1405-7","article-title":"A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis","volume":"29","author":"Pollono EN","year":"2010","unstructured":"Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol. 2010, 29:947-55. 10.1007\/s10067-010-1405-7","journal-title":"Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2016.1183460","article-title":"Effect of tumor necrosis factor-\u03b1 inhibitors on ambulatory 24-h blood pressure","volume":"26","author":"Grossman C","year":"2017","unstructured":"Grossman C, Bornstein G, Leibowitz A, et al.. Effect of tumor necrosis factor-\u03b1 inhibitors on ambulatory 24-h blood pressure. Blood Press. 2017, 26:24-9. 10.1080\/08037051.2016.1183460","journal-title":"Blood Press"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000446","article-title":"Tumor necrosis factor-\u03b1 inhibitor use and the risk of incident hypertension in patients with rheumatoid arthritis","volume":"27","author":"Desai RJ","year":"2016","unstructured":"Desai RJ, Solomon DH, Schneeweiss S, et al.. Tumor necrosis factor-\u03b1 inhibitor use and the risk of incident hypertension in patients with rheumatoid arthritis. Epidemiology. 2016, 27:414-22. 10.1097\/EDE.0000000000000446","journal-title":"Epidemiology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465576-cardiovascular-outcomes-and-vascular-surrogate-markers-in-rheumatoid-arthritis-patients-treated-with-anti-tumour-necrosis-factor-tnf-therapy-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:46:37Z","timestamp":1772203597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465576-cardiovascular-outcomes-and-vascular-surrogate-markers-in-rheumatoid-arthritis-patients-treated-with-anti-tumour-necrosis-factor-tnf-therapy-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.104389","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}